Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2006

Dyax and CSIRO form Antibody Discovery Collaboration

  • Dyax and the Division of Molecular and Health Technologies of the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national scientific research agency, entered into a collaboration for the discovery and development of therapeutic antibodies to treat cancer.

    During the discovery phase of the collaboration, Dyax will use its antibody libraries to screen for clinical candidates, and CSIRO will provide reagents and in vitro assays as well as certain in vivo and preclinical development work. Upon successful completion of the discovery work, CSIRO and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global codevelopment and commercialization agreement.

    “We are pleased to have entered into this collaboration with CSIRO, and are confident that Dyax’s antibody libraries will again produce quality clinical leads that may provide a novel approach to treating cancer,” remarks Henry E. Blair, chairman and CEO of Dyax.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »